GTC Biotherapeutics (fka GTCB)

[cash2go]

Why no ATryn sales in Europe?

Apporved in 2006

FRAMINGHAM, MA - August 2, 2006 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) reported today that the European Commission has granted market authorization to ATryn®, GTC's recombinant form of human antithrombin, for the prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency

http://www.gtc-bio.com/pressreleases/pr080206.html

Looks like a lot of selling on the news as ATryn will not be a big seller? The dilution coming from recent financing activities will also be weighing shares down for a while. Great Headlines should bring in the traders Monday. Long term is what I'm interested in.
Any other companies working in genetically altered animals producing human protiens that look intersting to anyone.

Zero knowledge base in this one, myself. Hope to see the long term investors weigh in on the potential here and what would be a good entry point.